Vascular endothelial growth factor (VEGF) inhibitorsin cancer therapy: An update

Jade Homsi, Lori C. Kim, Pamela N. Munster, Catherine Chodkiewicz, Adil Daud

Research output: Contribution to journalReview article

Abstract

Recent progress in the molecular and biological understanding of the VEGF pathway provides us with novel and promising therapeutic strategies and targets for overcoming cancer. VEGF plays an important role in tumor growth and metastasis. It is recognized as an essential regulator of normal and abnormal blood vessel growth. Therapies designed to target VEGF have been in development for the past few years and as a result VEGF inhibitors are now available as standard therapy or as part of clinical trials. Bevacizumab was the first anti-VEGF therapy and was approved for use in metastatic colorectal cancer after showing significant improvement of survival. Recent trials with several VEGF inhibitors in breast, non-small cell lung, ovarian, kidney cancers and melanoma have shown very encouraging results. This review will discuss the role of VEGF in angiogenesis and malignancy, VEGF inhibitors, and the recent clinical trials of their use in different tumors.

Original languageEnglish (US)
Pages (from-to)127-136
Number of pages10
JournalWomen's Oncology Review
Volume6
Issue number42067
DOIs
StatePublished - Jan 1 2006

Fingerprint

Vascular Endothelial Growth Factor A
Neoplasms
Therapeutics
Clinical Trials
Kidney Neoplasms
Growth
Ovarian Neoplasms
Blood Vessels
Colorectal Neoplasms
Melanoma
Breast
Neoplasm Metastasis
Lung

ASJC Scopus subject areas

  • Oncology

Cite this

Vascular endothelial growth factor (VEGF) inhibitorsin cancer therapy : An update. / Homsi, Jade; Kim, Lori C.; Munster, Pamela N.; Chodkiewicz, Catherine; Daud, Adil.

In: Women's Oncology Review, Vol. 6, No. 42067, 01.01.2006, p. 127-136.

Research output: Contribution to journalReview article

Homsi, Jade ; Kim, Lori C. ; Munster, Pamela N. ; Chodkiewicz, Catherine ; Daud, Adil. / Vascular endothelial growth factor (VEGF) inhibitorsin cancer therapy : An update. In: Women's Oncology Review. 2006 ; Vol. 6, No. 42067. pp. 127-136.
@article{6702ceb8b8e943968f7e2a3bfd9ea7b8,
title = "Vascular endothelial growth factor (VEGF) inhibitorsin cancer therapy: An update",
abstract = "Recent progress in the molecular and biological understanding of the VEGF pathway provides us with novel and promising therapeutic strategies and targets for overcoming cancer. VEGF plays an important role in tumor growth and metastasis. It is recognized as an essential regulator of normal and abnormal blood vessel growth. Therapies designed to target VEGF have been in development for the past few years and as a result VEGF inhibitors are now available as standard therapy or as part of clinical trials. Bevacizumab was the first anti-VEGF therapy and was approved for use in metastatic colorectal cancer after showing significant improvement of survival. Recent trials with several VEGF inhibitors in breast, non-small cell lung, ovarian, kidney cancers and melanoma have shown very encouraging results. This review will discuss the role of VEGF in angiogenesis and malignancy, VEGF inhibitors, and the recent clinical trials of their use in different tumors.",
author = "Jade Homsi and Kim, {Lori C.} and Munster, {Pamela N.} and Catherine Chodkiewicz and Adil Daud",
year = "2006",
month = "1",
day = "1",
doi = "10.3109/14733400600739731",
language = "English (US)",
volume = "6",
pages = "127--136",
journal = "Women's Oncology Review",
issn = "1473-3404",
publisher = "Parthenon Publishing Group",
number = "42067",

}

TY - JOUR

T1 - Vascular endothelial growth factor (VEGF) inhibitorsin cancer therapy

T2 - An update

AU - Homsi, Jade

AU - Kim, Lori C.

AU - Munster, Pamela N.

AU - Chodkiewicz, Catherine

AU - Daud, Adil

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Recent progress in the molecular and biological understanding of the VEGF pathway provides us with novel and promising therapeutic strategies and targets for overcoming cancer. VEGF plays an important role in tumor growth and metastasis. It is recognized as an essential regulator of normal and abnormal blood vessel growth. Therapies designed to target VEGF have been in development for the past few years and as a result VEGF inhibitors are now available as standard therapy or as part of clinical trials. Bevacizumab was the first anti-VEGF therapy and was approved for use in metastatic colorectal cancer after showing significant improvement of survival. Recent trials with several VEGF inhibitors in breast, non-small cell lung, ovarian, kidney cancers and melanoma have shown very encouraging results. This review will discuss the role of VEGF in angiogenesis and malignancy, VEGF inhibitors, and the recent clinical trials of their use in different tumors.

AB - Recent progress in the molecular and biological understanding of the VEGF pathway provides us with novel and promising therapeutic strategies and targets for overcoming cancer. VEGF plays an important role in tumor growth and metastasis. It is recognized as an essential regulator of normal and abnormal blood vessel growth. Therapies designed to target VEGF have been in development for the past few years and as a result VEGF inhibitors are now available as standard therapy or as part of clinical trials. Bevacizumab was the first anti-VEGF therapy and was approved for use in metastatic colorectal cancer after showing significant improvement of survival. Recent trials with several VEGF inhibitors in breast, non-small cell lung, ovarian, kidney cancers and melanoma have shown very encouraging results. This review will discuss the role of VEGF in angiogenesis and malignancy, VEGF inhibitors, and the recent clinical trials of their use in different tumors.

UR - http://www.scopus.com/inward/record.url?scp=85027916117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027916117&partnerID=8YFLogxK

U2 - 10.3109/14733400600739731

DO - 10.3109/14733400600739731

M3 - Review article

AN - SCOPUS:85027916117

VL - 6

SP - 127

EP - 136

JO - Women's Oncology Review

JF - Women's Oncology Review

SN - 1473-3404

IS - 42067

ER -